azacitidine has been researched along with Genetic Diseases, X-Chromosome Linked in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aouba, A; Bouscary, D; Comont, T; Dion, J; Fenaux, P; Georgin-Lavialle, S; Heiblig, M; Kosmider, O; Le Guenno, G; Mathian, A; Mekinian, A; Rieu, V; Rivière, E; Rossignol, J; Terrier, B; Terriou, L; Vinit, J | 1 |
| Chonabayashi, K; Inagaki, A; Kawabata, H; Morimoto, Y; Nagao, M; Nakanishi, K; Narita, M; Nishikawa, M; Okubo, C; Takaori-Kondo, A; Yamasaki-Morita, M; Yoshida, Y | 1 |
2 other study(ies) available for azacitidine and Genetic Diseases, X-Chromosome Linked
| Article | Year |
|---|---|
Azacitidine for patients with Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic syndrome (VEXAS) and myelodysplastic syndrome: data from the French VEXAS registry.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Female; France; Genes, X-Linked; Genetic Diseases, X-Linked; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Registries; Skin Diseases, Genetic | 2022 |
Azacitidine is a potential therapeutic drug for pyridoxine-refractory female X-linked sideroblastic anemia.
Topics: 5-Aminolevulinate Synthetase; Aminolevulinic Acid; Anemia, Sideroblastic; Azacitidine; Female; Genetic Diseases, X-Linked; Humans; Pharmaceutical Preparations; Pyridoxine | 2022 |